TY - JOUR
KW - Humans
KW - *Diabetes Mellitus, Type 2/drug therapy/epidemiology/complications
KW - *Dipeptidyl-Peptidase IV Inhibitors/adverse effects
KW - Cohort Studies
KW - Sulfonylurea Compounds/adverse effects
KW - *Skin Neoplasms/chemically induced/epidemiology/complications
KW - *Melanoma/epidemiology/complications
KW - Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
KW - Dipeptidyl Peptidase 4
KW - Drug Effects
KW - Medical Oncology
KW - pharmacoepidemiology
AU - R. Pradhan
AU - O. H. Y. Yu
AU - R. Platt
AU - L. Azoulay
AD - Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Québec, Canada.
Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Montreal, Québec, Canada.
Division of Endocrinology, Jewish General Hospital, Montreal, Québec, Canada.
Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Québec, Canada laurent.azoulay@mcgill.ca.
AN - 37949470
BT - BMJ Open Diabetes Res Care
C2 - PMC10649616
DO - 10.1136/bmjdrc-2023-003550
DP - NLM
ET - 2023/11/11
LA - eng
M1 - 6
N1 - 2052-4897
Pradhan, Richeek
Yu, Oriana H Y
Platt, Robert W
Azoulay, Laurent
Orcid: 0000-0001-5162-3556
FDN-143328/CIHR/Canada
Journal Article
Research Support, Non-U.S. Gov't
England
BMJ Open Diabetes Res Care. 2023 Nov;11(6):e003550. doi: 10.1136/bmjdrc-2023-003550.
PY - 2023
SN - 2052-4897
T2 - BMJ Open Diabetes Res Care
TI - Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study
VL - 11
ER -